ProShare Advisors LLC announced in its latest Form 13F filing with the Securities and Exchange Commission that it increased its holdings in Vir Biotechnology, Inc. (NASDAQ:VIR – Free Report ) by 8.4% in the first quarter. The fund acquired an additional 2,035 shares during the period, bringing its holdings to 26,392 shares of the company. ProShare Advisors LLC’s holdings in Vir Biotechnology were valued at $267,000 as of the latest SEC filing.
A number of other institutional investors also recently bought and sold shares in the company. Vanguard Group increased its holdings in Vir Biotechnology by 9.8% in the fourth quarter. The firm now holds 12,297,139 shares of the company’s stock, valued at $123,709,000. It purchased an additional 1,096,473 shares in the last quarter. Mirae Asset Global Investments increased its holdings in Vir Biotechnology by 268.9% in the fourth quarter. The firm now holds 212,902 shares of the company’s stock, valued at $2,142,000. It purchased an additional 155,196 shares in the last quarter. Panagora Asset Management acquired a new stake in Vir Biotechnology in the fourth quarter, valued at approximately $951,000. Nordea Investment Management AB increased its holdings in Vir Biotechnology by 58.7% in the first quarter. Nordea Investment Management AB now owns 235,664 shares of the company’s stock valued at $2,408,000 after purchasing an additional 87,190 shares in the last quarter. Finally, Louisiana State Employees Retirement System bought a new stake in Vir Biotechnology shares worth about $434,000 in the fourth quarter. 65.32% of the stock is owned by institutional investors.
Insider Activities
In other news, Director, Saira Ramasastry sold 4,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $10.95, for a total transaction value of $43,800.00. Following the sale, the director now owns 14,619 shares of the company’s stock, valued at $160,078.05. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 15.60% of the company’s stock.
Vir Biotechnology shares rose 0.4%
NASDAQ:VIR opened trading at $10.70 on Friday. The company’s 50-day moving average price is $9.89 and its 200-day moving average price is $9.82. Vir Biotechnology, Inc.’s 52-week low is $7.61 and its 52-week high is $14.27. The company has a market cap of $1.46 billion, a price-to-earnings ratio of -2.67 and a beta of 0.48.
Vir Biotechnology (NASDAQ:VIR – get free report ) announced its quarterly earnings on Thursday, May 2nd. The company reported quarterly EPS of ($0.48), beating analysts’ consensus estimates of ($0.99) by $0.51. Vir Biotechnology had a net margin of -677.69% and a return on equity of -32.58%. The company had revenue of $56.38 million for the quarter, compared to analysts’ estimates of $11.71 million. Year-over-year earnings were ($1.06). Quarterly revenue was down 10.5% year-over-year. Sell-side analysts expect Vir Biotechnology, Inc. to post earnings of -$3.57 per share for the current year.
Wall Street analysts predict growth
VIR has been the subject of numerous research reports. HC Wainwright reaffirmed their “buy” rating on shares of Vir Biotechnology and set a $110.00 price target in a research note on Wednesday, June 5th. Needham & Company LLC raised their price target on shares of Vir Biotechnology from $15.00 to $19.00 and gave the stock a “buy” rating in a report on Wednesday, June 5th. Morgan Stanley raised their price target on shares of Vir Biotechnology from $12.00 to $15.00 and gave the stock an “equal weight” rating in a report on Thursday, June 6th. Finally, JPMorgan Chase & Co. raised their price target on shares of Vir Biotechnology from $10.00 to $12.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd. Three investment analysts have rated the stock with a “hold” rating, and two have rated it with a “buy” rating, according to data from MarketBeat.com. The company’s current consensus rating is a “hold,” with an average price target of $34.00, according to data from MarketBeat.com.
View VIR’s latest stock report
Vir Biotechnology Company Profile
(Free report)
Vir Biotechnology, Inc., a commercial-stage immunology company, is developing therapeutics for the treatment and prevention of serious infectious diseases, including tobevivalte + elevusiran for chronic hepatitis delta, elevusiran + PEG-IFN-a, tobevivalte ± elevusiran ± PEG-IFN-a, and elevusiran + TLR8 + PD-1 for chronic hepatitis B, VIR-1388 in combination with Cure mAb for the treatment of human immunodeficiency virus, VIR-8190 for the treatment of respiratory syncytial virus/human metapneumovirus, VIR-2981 for the treatment of influenza, VIR-1949 for the treatment of precancerous HPV lesions, and VIR07229 and sotrovimab for the treatment of COVID-19 infection under the brand name Xevudy.
reference
Want to see what other hedge funds are holding VIR? Visit HoldingsChannel.com to get the latest 13F filings and insider transactions for Vir Biotechnology, Inc. (NASDAQ:VIR – FREE Report).
Get Vir Biotechnology News and Ratings Daily – Enter your email address below to receive a concise summary of the latest news and analyst ratings on Vir Biotechnology and related companies every day with MarketBeat.com’s free email newsletter.
